PTSM: Pharmaceutical Technology Sourcing and Management-04-08-2009

The financial crisis is adding further injury to already weakened prospects for the pharmaceutical industry.

Follow-on biologics or biosimilars offer a niche growth market for the pharmaceutical industry. As the process for establishing a regulatory pathway for biosimilars is debated, companies, including Big Pharma, are positioning themselves to gain this piece of the pharmaceutical pie.

When the business environment returns to "normal," our industry may appear quite different.